The ELAINE-3 study

About the ELAINE-3 study:

Study purpose

The ELAINE-3 study will assess the efficacy, safety, and tolerability of the combination of lasofoxifene and abemaciclib compared with that of fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men with locally advanced or metastatic estrogen receptor-positive/human epidermal growth factor 2-negative (ER+/HER2-) breast cancer who have disease progression on an aromatase inhibitor (AI)* in combination with either palbociclib or ribociclib as their first hormonal treatment for metastatic disease and who have an estrogen receptor 1 (ESR1) mutation.1

*AIs include Arimidex® (anastrozole), Femara® (letrozole), or Aromasin® (exemestane). Cyclin-dependent kinase 4/6 inhibitors (CDK 4/6 inhibitors) include Kisqali® (ribociclib), Ibrance® (palbociclib), and Verzenio® (abemaciclib). All product names, trademarks, and registered trademarks are property of their respective owners.

Focusing on your quality of life

In addition to assessing efficacy specific to progression-free survival (PFS), data collection will also include patient-reported outcomes (PROs) via the FACT-B (Functional Assessment of Cancer Therapy – Breast) and FACT-ES (Functional Assessment of Cancer Therapy – Endocrine Symptoms) survey tools. These are validated tools that focus on quality-of-life issues for patients who are on endocrine therapy. The PROs will be collected in both treatment arms, as all participants will be on a form of endocrine therapy.1

Lori’s story

Learn about the journey of a potential patient to the ELAINE-3 clinical trial in this fictional story.

Sermonix is proud to announce enrollment into ELAINE-3

ELAINE-3 is a large, randomized, phase 3 study with clinical trial sites across the United States, Europe, Asia-Pacific, Israel, and Canada.

If you are interested in learning more about the study and finding out if you qualify to enroll,

Send me the latest news

By subscribing, you agree to receive the latest news and updates from us.

Reference: 1. Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (ELAINEIII). Identifier: NCT05696626. Updated January 27, 2023. Accessed June 20, 2023.